Drug Profile
CS 502
Alternative Names: CS-502Latest Information Update: 12 May 2008
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Class Analgesics; Anti-inflammatories
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation; Pain
Most Recent Events
- 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
- 25 May 2004 Phase-II clinical trials in Inflammation in USA (PO)
- 25 May 2004 Phase-II clinical trials in Pain in USA (PO)